Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Bcl-2-like protein 1 is a protein encoded by the BCL2L1 gene. It belongs to BCL-2 family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulate cell death by blocking the voltage-dependent anion channel by binding to it and preventing the release of the caspase activator (CYC1) from the mitochondrial membrane. It acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 3 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease and Musculoskeletal Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Hepatocellular Carcinoma, Small-Cell Lung Cancer, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Bladder Cancer, Blood Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelomonocytic Leukemia (CMML), Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Fibrosis, Follicular Lymphoma, Gastric Cancer, Head And Neck Cancer, Hematological Tumor, Hormone-Sensitive Prostate Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lymphoblastic Lymphoma, Mantle Cell Lymphoma, Metastatic Melanoma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Myelodysplastic Syndrome, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroendocrine Tumors, Nodal Marginal Zone B-Cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Sezary Syndrome, Splenic Marginal Zone B-Cell Lymphoma, T-Cell Lymphomas and Unspecified B-Cell Lymphomas.
The latest report, outlays comprehensive information on the Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook